The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Chemotherapy‐induced neutropenia: Risks, consequences, and new directions for its management
Open accessAbstract
Cytotoxic chemotherapy suppresses the hematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the most serious hematologic toxicity, is associated with the risk of life‐threatening infections as well as chemotherapy dose reductions and delays that may compromise treatment outcomes. The authors reviewed the recent literature to provide an update on research in chemotherapy‐induced neutropenia and its complications and impact, and they discuss the implications of this work for improving the management of patients with cancer who are treated with myelosuppressive chemotherapy. Despite its importance as the primary dose‐limiting toxicity of chemotherapy, much concerning neutropenia and its consequences and impact remains unknown. Recent surveys indicate that neutropenia remains a prevalent problem associated with substantial morbidity, mortality, and costs. Much research has sought to identify risk factors that may predispose patients to neutropenic complications, including febrile neutropenia, in an effort to predict better which patients are at risk and to use preventive strategies, such as prophylactic colony‐stimulating factors, more cost‐effectively. Neutropenic complications associated with myelosuppressive chemotherapy are a significant cause of morbidity and mortality, possibly compromised treatment outcomes, and excess healthcare costs. Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs. Cancer 2004;100:228–37. © 2003 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BODEY, G. P., BUCKLEY, M., SATHE, Y. S., & FREIREICH, E. J. (1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-2-328 · Cited by 2,469
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., Picozzi, V., Rausch, G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250305 · Cited by 1,390
Self-citationKlastersky, J., Paesmans, M., Rubenstein, E. B., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., Rolston, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3038 · Cited by 1,171
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,049
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Self-citationManagement of Cancer in the Older Person: A Practical Approach
Balducci, L., & Extermann, M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-224 · Cited by 939
Schimpff, S., Satterlee, W., Young, V. M., & Serpick, A. (1971) · New England Journal of Medicine · doi:10.1056/nejm197105132841904 · Cited by 673
Green, M. D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R. I., Samonigg, H., Clemens, M. R., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg019 · Cited by 586
Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, Wood, W. C., Weiss, R. B., Ferree, C. R., Muss, H. B., Green, M. R., Norton, L., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1205 · Cited by 577
Trillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., Depierre, A., Johnson, P., Decoster, G., Tomita, D., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90376-q · Cited by 543
Holmes, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.727 · Cited by 537
Lyman, G. H., Dale, D. C., & Crawford, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.002 · Cited by 464
Self-citationKwak, L. W., Halpern, J., Olshen, R. A., & Horning, S. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.963 · Cited by 431
Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases
Hruban, R. H., Shiu, M. H., Senie, R. T., & Woodruff, J. M. (1990) · Cancer · doi:10.1002/1097-0142(19900915)66:6<1124::aid-cncr2820660608>3.0.co;2-t · Cited by 364
Talcott, J. A. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.148.12.2561 · Cited by 363
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer
Rubenstein, E. B., Rolston, K., Escalante, C., Manzullo, E., Hughes, P., Fender, A., Elting, L., Bodey, G. P., Holmes, F., Loewy, J., et al. (1993) · Cancer · doi:10.1002/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h · Cited by 286
General guidelines for the management of older patients with cancer.
Balducci, L., & Yates, J. (2000) · PubMed · Cited by 275
Lyman, G. H., Kuderer, N. M., & Djulbegovic, B. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01036-7 · Cited by 221
Self-citationThe economics of febrile neutropenia: implications for the use of colony-stimulating factors
Lyman, G. H., Kuderer, N., Greene, J., & Balducci, L. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00222-6 · Cited by 192
Self-citationDees, E. C., O'reilly, S., Goodman, S. N., Sartorius, S., Levine, M. A., Jones, R. J., Grochow, L. B., Donehower, R. C., & Fetting, J. H. (2000) · Cancer Investigation · doi:10.3109/07357900009012191 · Cited by 180
Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., Morel, P., Herbrecht, R., Reyes, F., & Coiffier, B. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058619 · Cited by 174
Empiric antibiotic therapy for granulocytopenic cancer patients.
Sc, S. (1986) · The American Journal of Medicine · Cited by 171
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.
Blay, J., Chauvin, F., Cesne, A. L., Anglaret, B., Bouhour, D., Lasset, C., Freyer, G., Philip, T. O., & Biron, P. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.636 · Cited by 169
Gómez, H., Hidalgo, M., Casanova, L., Colomer, R., Pen, D. L., Otero, J., Rodríguez, W., Carracedo, C., Cortés-Funes, H., & Vallejos, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2065 · Cited by 169
Predictors of tolerance to chemotherapy in older cancer patients
Extermann, M., Chen, H., Cantor, A. B., Corcoran, M. B., Meyer, J. S., Grendys, E. C., Cavanaugh, D., Antonek, S., Camarata, A., Haley, W. E., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00090-4 · Cited by 157
Silber, J. H., Fridman, M., DiPaola, R. S., Erder, M. H., Pauly, M. V., & Fox, K. R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2392 · Cited by 149
Morrison, V. A., Picozzi, V. J., Scott, S., Pohlman, B. L., Dickman, E., Lee, M. W., Lawless, G. D., Kerr, R. O., Caggiano, V., Delgado, D., et al. (2001) · Clinical Lymphoma · doi:10.3816/clm.2001.n.011 · Cited by 144
Mayers, C., Panzarella, T., & Tannock, I. F. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2246::aid-cncr1255>3.0.co;2-4 · Cited by 132
Science and pragmatism in the treatment and prevention of neutropenic infection
Klastersky, J. A. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.suppl_4.13 · Cited by 129
New Trends in Patient Management: Risk-Based Therapy for Febrile Patients with Neutropenia
Rolston, K. V. I. (1999) · Clinical Infectious Diseases · doi:10.1086/598624 · Cited by 123
Intragumtornchai, T., Sutheesophon, J., Sutcharitchan, P., & Swasdikul, D. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009089435 · Cited by 104
Filgrastim (r-metHuG-CSF) in clinical practice
Morstyn, G., & Dexter, T. M. (1994) · Cited by 87
The geriatric cancer patient: equal benefit from equal treatment.
Balducci, L. (2001) · PubMed · Cited by 86
Link, B. K., Budd, G. T., Scott, S., Dickman, E., Paul, D., Lawless, G. D., Lee, M. W., Fridman, M., Ford, J. M., Carter, W. B., et al. (2001) · Cancer · Cited by 80
Chrischilles, E. A., Delgado, D. J., Stolshek, B. S., Lawless, G. D., Fridman, M., Carter, W. B., & for the Oncology Practice Pattern Study Working Group (2002) · Cancer Control · doi:10.1177/107327480200900303 · Cited by 77
Rolston, K. V. I., & Tarrand, J. J. (1999) · Clinical Infectious Diseases · doi:10.1086/520247 · Cited by 73
The Geriatric Cancer Patient: Equal benefit from Equal treatment
(2001) · Cancer Control · doi:10.1177/107327480100802s01 · Cited by 43
Wilson-Royalty, M., Lawless, G. D., Palmer, C., & Brown, R. (2001) · Journal of Oncology Pharmacy Practice · doi:10.1191/1078155201jp084oa · Cited by 35
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Self-citationTumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,017
Metadata
- Authors
- Crawford, J., Dale, D. C., & Lyman, G. H.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-01-05
- Volume
- 100
- Issue
- 2
- Pages
- 228-237
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1546909751
- Cited by
- 882
- References
- 40
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.